Impact of dose-intense chemotherapy on the development of permanent drug resistance
Affiliations
- PMID: 3686044
Item in Clipboard
Impact of dose-intense chemotherapy on the development of permanent drug resistance
Semin Oncol.
1987 Dec.
Abstract
Using a somatic mutation theory for drug resistance, dose intense regimens are shown to be superior in increasing the likelihood of no doubly resistant cells and in curing the tumor. Consideration of this model suggests that dose intensity of early chemotherapy cycles should be calculated separately and correlated with treatment outcome.
Similar articles
-
Stochastic modeling of drug resistance in cancer.J Theor Biol. 2006 Apr 7;239(3):351-66. doi: 10.1016/j.jtbi.2005.08.003. Epub 2005 Sep 27. J Theor Biol. 2006. PMID: 16194548
-
Advances in cancer therapeutics: chemotherapy.Prog Clin Biol Res. 1983;132A:47-69. Prog Clin Biol Res. 1983. PMID: 6634746
-
Modelling chemotherapy resistance in palliation and failed cure.J Theor Biol. 2009 Mar 21;257(2):292-302. doi: 10.1016/j.jtbi.2008.12.006. Epub 2008 Dec 11. J Theor Biol. 2009. PMID: 19135065
-
New approaches to adjuvant chemotherapy for breast cancer.Pharmacotherapy. 1996 May-Jun;16(3 Pt 2):88S-93S. Pharmacotherapy. 1996. PMID: 8726587 Review.
-
Evolving concepts in the systemic drug therapy of breast cancer.Semin Oncol. 1997 Aug;24(4 Suppl 10):S10-3-S10-10. Semin Oncol. 1997. PMID: 9275000 Review.
Cited by
-
Tolerability and efficacy of GM-CSF [Leucomax] in patients with small cell lung cancer treated with intensive chemotherapy.Med Oncol. 1996 Dec;13(4):199-205. doi: 10.1007/BF02990932. Med Oncol. 1996. PMID: 9152970
-
What Tumor Dynamics Modeling Can Teach us About Exploiting the Stem-Cell View for Better Cancer Treatment.Cancer Inform. 2015 Feb 24;14(Suppl 2):25-36. doi: 10.4137/CIN.S17294. eCollection 2015. Cancer Inform. 2015. PMID: 25780337 Free PMC article. Review.
-
Neoadjuvant Dose-Dense and Dose-Intensified Chemotherapy in Breast Cancer - Review of the Literature.Breast Care (Basel). 2016 Feb;11(1):13-20. doi: 10.1159/000444543. Epub 2016 Feb 23. Breast Care (Basel). 2016. PMID: 27051390 Free PMC article. Review.
-
The use of granulocyte colony-stimulating factor to shorten the interval between cycles of mitomycin C, vindesine, and cisplatin chemotherapy in non-small-cell lung cancer.Cancer Chemother Pharmacol. 1992;31(3):182-6. doi: 10.1007/BF00685545. Cancer Chemother Pharmacol. 1992. PMID: 1281446 Clinical Trial.
-
Dose-Dense Chemotherapy: Principles, Clinical Results and Future Perspectives.Breast Care (Basel). 2008;3(4):251-255. doi: 10.1159/000148914. Epub 2008 Aug 20. Breast Care (Basel). 2008. PMID: 21076605 Free PMC article.